Navigation Links
Study shows new treatment strategy effective for certain lung cancers
Date:3/10/2011

New Orleans, LA LSU oncologist Vince D. Cataldo, MD, is the lead author of a review article reporting two chemotherapy drugs now indicated for second and third-line therapy in patients with advanced non-small-cell lung cancer are remarkably effective in treating a certain subset of these patients. Dr. Cataldo, a Clinical Assistant Professor of Medicine at LSU Health Sciences Center New Orleans School of Medicine, practicing at LSU's Earl K. Long Medical Center and Hematology-Oncology Clinic in Baton Rouge, and his colleagues say these drugs should be considered as a first-line treatment in people who are known to carry an Epidermal Growth Factor Receptor (EGFR) mutation. The paper is published in the March 10, 2011 issue of the New England Journal of Medicine.

The drugs, Erlotinib and Gefitinib, which are in a class of highly-specific small molecule tyrosine kinase inhibitors, work by blocking the activation of EGFR which is involved in cell survival and growth, as well as the development of a nourishing blood supply and metastasis.

"Targeting the genetic mutation contributing to the development of the cancer, this class of drugs produced a response rate that exceeded 70% in these patients," notes Dr. Cataldo.

The drugs, taken by mouth, also had fewer side effects. Unlike traditional cytotoxic agents, Erlotinib and Gefitinib do not typically cause myelosuppression, neuropathy, alopecia, or severe nausea.

Lung cancer, the leading cause of cancer-related death worldwide, accounted for an estimated 157,300 deaths in the United States in 2010. Approximately 85 to 90% of all cases of lung cancer are nonsmall-cell lung cancer (NSCLC) which is also associated with smoking. Advanced-stage NSCLC is currently considered an incurable disease for which standard chemotherapy provides marginal improvement in overall survival at the expense of substantial morbidity and mortality. Furthermore, less than 30% of patients with meta
'/>"/>

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-568-4806
Louisiana State University Health Sciences Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. Study finds usage of, recommendations for supplements common within various physician specialties
2. Study provides explanation for connection between low birth weight and obesity later in life
3. New UF study shows some sharks follow mental map to navigate seas
4. Study shows how plants sort and eliminate genes over millennia
5. MBARI and Monterey Bay National Marine Sanctuary to study effects of shipping containers lost at sea
6. Rensselaer professor utilizing New York state grant to study adult stem cells
7. Study analyzes role of PARP enzyme in eukaryotes
8. Fossil bird study describes ripple effect of extinction in animal kingdom
9. University of Missouri researcher study provides insight into how corn makes hormones
10. Rainwater harvest study finds roofing material affects water quality
11. A study reveals the keys to the locomotion of snails
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/kx9zp8/military ) ... Electro-Optical / Infrared Systems Market by Type, by ... to 2020" report to their offering. ... expected to reach $16.35 billion by 2020, to ... report segments the military electro-optical/infrared systems market on ...
(Date:2/11/2015)... February 11, 2015 ... "Access Control Market by Product (Cards and Readers, Biometrics, ... Defense, Government, Industrial, Healthcare, Education) and By Geography - Global ... MarketsandMarkets, the Access Control Market is expected ... at a CAGR of 10.6% between 2014 ...
(Date:2/5/2015)... SAN DIEGO , Jan. 26, 2015   Epic ... treatment of cancer, today announced that Murali Prahalad , ... Personalized Medicine World Conference (PMWC) 2015: Silicon Valley, ... Mountain View, Calif. on January 26-28, ... entitled, "CTCs Come of Age as Biomarkers." Last year, Epic ...
Breaking Biology News(10 mins):Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2
... Chapel Hill, NC Rho proteins have been described ... migration, cell proliferation, cell death, gene expression, and multiple ... of Rho proteins is important to illuminating cellular mechanisms ... cell misbehavior. When cells multiply too rapidly, multiply ...
... April 19, 2010 Low back pain (or lumbago) is a ... suitcase. What is the best way to remedy the situation? An ... according to a new study published in the Journal of ... to bring about physiological change to help the development and endurance ...
... Solomons, Md. (April 19, 2010) For his groundbreaking ... University of Maryland Center for Environmental Science researcher Dr. ... Maryland,s highest honor, the Regents, Faculty Award for Excellence. ... Dr. Secor,s research has focused on species that often ...
Cached Biology News:Research pinpoints action of protein linked to key molecular switch 2Exercise therapy for low back pain 2UMCES fisheries biologist Dr. David Secor receives USM Regent's Faculty Award for research 2
(Date:2/26/2015)... , Feb. 26, 2015  Epic Sciences announced today ... will present at the 35th Annual Cowen and Company ... in the MIT Room, 3rd Floor. The conference will ... in Boston, Mass. Epic is developing diagnostic tests ... genomic and proteomic changes that occur during the course ...
(Date:2/26/2015)... Feb. 26, 2015 CytomX, a biotechnology company ... announced that Sean McCarthy , D. Phil., chief ... upcoming Cowen and Company 35 th Annual Health ... McCarthy,s presentation will take place at 4 p.m. EST ... CytomX Therapeutics develops Probody™ therapeutics for the treatment ...
(Date:2/26/2015)... 26, 2015 Phosphate Therapeutics, ... the first pivotal trial of PT20 in subjects ... disease (DD-CKD), has completed as the pre-specified number ... invented by leading UK-based scientists from the Medical ... is a novel phosphate binder that is based ...
(Date:2/25/2015)... Today, BioMed Realty Trust, Inc. (NYSE: ... of promotions and additions to its leadership team focused ... shareholder returns through strategic investments in real estate at ... the innovation sector. The company also ... leaving his role as President and Chief Operating Officer ...
Breaking Biology Technology:Epic Sciences to Present at 35th Annual Cowen and Company Health Care Conference 2Phosphate Therapeutics Announces Completion of Subject Recruitment Into the PEACH Pivotal Phase 2 Study of its Novel Phosphate Binder (PT20) for the Treatment of Hyperphosphataemia 2Phosphate Therapeutics Announces Completion of Subject Recruitment Into the PEACH Pivotal Phase 2 Study of its Novel Phosphate Binder (PT20) for the Treatment of Hyperphosphataemia 3BioMed Realty Announces Realignment To Leverage Depth Of Life Science Real Estate Expertise And Increase Shareholder Value 2BioMed Realty Announces Realignment To Leverage Depth Of Life Science Real Estate Expertise And Increase Shareholder Value 3BioMed Realty Announces Realignment To Leverage Depth Of Life Science Real Estate Expertise And Increase Shareholder Value 4
... June 11 PRA International, a leading Clinical Research Organization, ... Association,s (EHA) 15th congress in Barcelona 10-13 June 2010 ... At PRA,s booth ... Berger , M.D., to discuss the key issues and latest developments in ...
... , FORT WORTH, Texas , ... of a new educational module "Exploring Biofilms," an,accredited, online course designed ... play in chronic wound infections. , ... "Bacterial biofilms are a ...
... CHICAGO , June 5 Genomic Health, ... six studies being presented at the American Society of Clinical ... and differences between stage II and III colon cancer, suggesting ... cancer test in patients with stage III disease, pending further ...
Cached Biology Technology:PRA International Exhibits at European Hematology Association Congress 2The Wound Institute(R) Launches Educational Course on Bacterial Biofilms 2The Wound Institute(R) Launches Educational Course on Bacterial Biofilms 3The Wound Institute(R) Launches Educational Course on Bacterial Biofilms 4Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting 2Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting 3Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting 4Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting 5Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting 6Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting 7Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting 8Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting 9
Request Info...
Mouse monoclonal [DJR3] to DcR1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
...
Rabbit polyclonal to Quinolinic acid ( Abpromise for all tested applications). Antigen: Synthetic quinolinic acid conjugated to bovine serum albumin....
Biology Products: